Small, E. J., Aggarwal, R. R., Huang, J., Sokolov, A., Zhang, L., Alumkal, J. J., … Beer, T. M. (2016). Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT). In Journal of Clinical Oncology (Vol. 34, pp. 5019–5019). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.5019

Small, Eric Jay, Rahul Raj Aggarwal, Jiaoti Huang, Artem Sokolov, Li Zhang, Joshi J. Alumkal, Jack Youngren, et al. “Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT).” In Journal of Clinical Oncology, 34:5019–5019. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.5019.

Small EJ, Aggarwal RR, Huang J, Sokolov A, Zhang L, Alumkal JJ, et al. Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 5019–5019.

Small, Eric Jay, et al. “Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT).” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 5019–5019. Crossref, doi:10.1200/jco.2016.34.15_suppl.5019.

Small EJ, Aggarwal RR, Huang J, Sokolov A, Zhang L, Alumkal JJ, Youngren J, Ryan CJ, Foye A, Reiter RE, Evans CP, Gleave M, Witte O, Stuart J, Goldstein TC, Thomas GV, True LD, Beltran H, Rubin MA, Beer TM. Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 5019–5019.